Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment

125I inhibited the NSCLC both in vivo and in vitro

Lung cancer is the main reason of cancer-linked death all over the world. Non-small cell lung cancer (NSCLC) patients always have an extremely poor prognosis. It is urgent to find novel treating methods. It was previously showed that ¹²⁵I brachytherapy had been applied to the lung cancer treatment. However, fundamental researches are limited. In the present study, we first explored the mechanism by which ¹²⁵I radiation induced arrest or apoptosis of the cell cycle and relevant protein expression. Furthermore, we explored its effect on the invasion. We found that ¹²⁵I significantly induced cell apoptosis through mitochondrial pathway, triggered S phase arrest via regulating cyclinA2, p21 and CDK6 expressions. Meanwhile, ¹²⁵I could inhibit invasion of NSCLC cells by altering the expression level of vimentin, N-cadherin and MMP-9. Furthermore, we confirmed the effects of ¹²⁵I on NSCLC cell growth in vivo. The results indicated that ¹²⁵I obviously inhibited the tumor growth. Thus, we determined that ¹²⁵I brachytherapy remarkably restrained NSCLC cellular growth and intrusion by inducing apoptosis, S phase arrest and corresponding protein expression.

MiR-130 exerts tumor suppressive function on the tumorigenesis of human non-small cell lung cancer by targeting PTEN

MicroRNAs (miRNAs) have been involved in some human malignancies and correlated with tumor progression. The dysregulation of miR-130 is found in various cancers and correlated with tumor proliferation and apoptosis. However, its expression and function in non-small cell lung cancer (NSCLC) have not been investigated yet. In this study, we demonstrated that miR-130 is significantly down-regulated in NSCLC tissue samples and cell lines. Low miR-130 expression was closely associated with lymph node metastasis, late stages of disease progression and diminished survival in NSCLC patients. The up-regulation of miR-130 could significantly inhibit NSCLC cell growth and enhance cell apoptosis both in vitro and in vivo. Whereas inhibition of miR-130 exerted opposite effects. Furthermore, dual-luciferase reporter assay confirmed that PTEN was regulated by miR-130 directly, and the knockdown of PTEN markedly abrogated the anti-growth effect of miR-130. Additionally, miR-130 was found positively correlated with PTEN in NSCLC specimens. In conclusion, our results suggested that the expression of miR-130 is significantly associated with the growth and apoptosis of NSCLS cells by targeting PTEN, whilst miR-130 may be a potential therapeutic target for NSCLC treatment.

Metachronous Lung Cancer: Clinical Characteristics and Effects of Surgical Treatment

The occurrence of a second lung tumor after surgical removal of lung cancer usually indicates a lung cancer metastasis, but sometimes a new lesion proves to be a new primary lung cancer, i.e., metachronous lung cancer. The goal of the present study was to conduct a clinical evaluation of patients with metachronous lung cancer and lung cancer metastasis, and to compare the early and distant outcomes of surgical treatment in both cancer types. There were 26 age-matched patients with lung cancer metastases and 23 patients with metachronous lung cancers, who underwent a second lung cancer resection. We evaluated the histological type of a resected cancer, the extent of thoracosurgery, the frequency of early postoperative complications, and the probability of 5-year survival after the second operation. The findings were that metachronous lung cancer was adenocarcinoma in 52% of patients, with a different histopathological pattern from that of the primary lung cancer in 74% of patients. In both cancer groups, mechanical resections were the most common surgery type (76% of all cases), with anatomical resections such as segmentectomy, lobectomy, or pneumectomy being much rarer conducted. The incidence of early postoperative complications in metachronous lung cancer and lung cancer metastasis (30% vs. 31%, respectively) and the probability of 5-year survival after resection of either cancer tumor (60.7% vs. 50.9%, respectively) were comparable. In conclusion, patients undergoing primary lung cancer surgery require a long-term follow-up due to the risk of metastatic or metachronous lung cancer. The likelihood of metachronous lung cancer and pulmonary lung cancer metastases, the incidence of postoperative complications, and the probability of 5-year survival after resection of metachronous lung cancer or lung cancer metastasis are similar.